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The modality dependent target margins to cover 95% of the 
tumor outer contour were 5.6 mm, 8.7 mm and 6.2 mm and 
resulted in median target volumes of 56 ml, 72 ml and 53 ml 
for CT, MRI and PET, respectively (Fig. 1b). 
 
Conclusion: In all modalities, delineated GTVs overestimated 
tumor volume. Nevertheless, some tumor volume was missed 
in all cases. Automated delineation on PET resulted in the 
smallest target volume compared to manual delineation on 
CT and MRI, while covering an equivalent amount of tumor. 
This study suggests that delineation or segmentation 
inaccuracies can be corrected using a margin between 5.6 
and 8.7 mm. 
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Purpose or Objective: Development of guidelines for the 
delineation of the gross tumor volume (GTV) on MRI is of 
utmost importance to benefit from the increased visibility of 
anatomical details and to achieve a more accurate and 
precise GTV delineation. In the ideal situation, the GTV 
corresponds to the histopathologically determined “true 
tumor volume”. In this work we developed and validated 
guidelines for GTV delineation on MRI by comparison with the 
tumor outline on histopathology as gold standard. 
 
Material and Methods: Twenty-seven patients with T3 or T4 
laryngeal or hypopharyngeal cancer underwent a MRI scan 
before total laryngectomy. After surgery, whole-mount 
hematoxylin-eosin stained (H&E) sections were obtained from 
the surgical specimen. One pathologist delineated all tumor 
tissue on the H&E sections (tumorH&E). The GTV was 
delineated on the MR images (T1 w, Gd-T1 w, T2 w) by three 
independent observers in two sessions. The first session 
(delineation 1) was performed according to clinical practice. 
In the second session (delineation 2) the observers used 
delineation guidelines derived from guidelines for detection 
of cartilage invasion on MRI: Volumes with increased signal 
intensity on T2w images and higher signal intensity on Gd-
T1w images than that of the tumor bulk were not included in 
the GTV. 
The reconstructed specimen was registered to the MR images 
in order to compare the GTV to the tumorH&E in 3D. Volumes 
and overlap parameters were analyzed. Distances between 
the GTV and the tumorH&E were calculated at locations 
where the tumorH&E was outside the GTV. Subsequently, a 
margin that accounted for the underestimation of the tumour 
was determined. Finally, target volumes were created by 
applying this margin to the GTV. 
 
Results: The median GTVs of delineation 1 (19.4 cm3) and of 
delineation 2 (15.8 cm3) were larger than the volume of the 
tumorH&E (10.5 cm3). However, target margins of 10.2 mm 
and 8.3 mm were needed for delineation 1 and 2 , 
respectively, to compensate for the underestimation of the 
tumor at specific locations. By adding this margin to the 
GTVs, the target volumes for delineation 1 (median: 117.6 
cm3, mean: 125.9 cm3, SD: 53.2 cm3) were significantly 
larger than those for delineation 2 (median 76.2 cm3, mean 
85.7 cm3, SD: 43.3 cm3). 
 
Conclusion: GTV delineation guidelines on MRI decreased the 
overestimation of the tumour, resulted in a smaller margin 
around the delineated GTV needed to include all tumor tissue 
and consequently resulted in smaller target volumes with the 
same tumor coverage. 
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Purpose or Objective: The benefit of upfront neck dissection 
(ND) in locally advanced head and neck cancer (HNC) treated 
with primary (chemo-) radiotherapy (CRT) is debated. 
Therefore, we retrospectively compared outcome and 
toxicity between patients with and without upfront ND 
followed by CRT. 
 
Material and Methods: Two-hundred sixty-four consecutive 
patients with HNC without metastases at diagnosis and with 
lymph node stage N2-N3 were included in 2 centers. Patients 
were all treated between January 2002 and December 2012, 
and received definitive CRT in center 1 and upfront ND 
followed by CRT in center 2. Clinical data and outcome were 
assessed retrospectively. Toxicity was scored using the LENT-
SOMA scale at 6, 12, 18 and 24 months after the end of 
treatment.Both patient groups were compared using a Chi-
square test for categorical variables or a Mann-Whitney U 
test for continuous variables. Descriptive statistics on overall 
survival (OS) is based on Kaplan Meier estimates. For all other 
time-to-event outcomes, cumulative incidence function (CIF) 
estimates were calculated. The difference between both 
groups on the different outcomes was analyzed using 
multivariable models, including group and prognostic patient- 
or tumor characteristics on which the 2 groups were 
different. All tests were two-sided, and a p-value of less than 
0.05 was considered statistically significant. 
 
Results: We included 150 patients in the group without ND 
(center 1) and 114 patients in the group with upfront ND 
(center 2). The group comparison is given in Table 1.  
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Based on this result, we decided to account for the 
differences in T stage, overall treatment time and 
concomitant treatment for the statistical analysis of outcome 
and toxicity. Mean follow up was 5.68 years in the group 
without ND and 5.83 years in the group with upfront ND. 
Local, regional and distant control after 2 years were 91.07% 
and 85.96% (p = 0.09), 89.22% and 83.27% (p = 0.12) and 
76.74% and 75.13% (p 0.92) in the group with and without 
upfront ND, respectively . We observed worse OS after 2 
years in the subgroup with upfront ND (48.01% vs. 70.79%, p = 
0.01). The difference in OS can be explained by more 
secondary primaries in this subgroup with upfront ND and 
more non-disease related deaths. We did not find a 
significant difference between both groups regarding edema 
and atrophy at 6, 12, 18 and 24 months (Figure 1). Regarding 
fibrosis, we found an overall trend towards worse outcome in 
the ND group at all time-points (p=0.06). A significantly 
higher proportion of severe fibrosis (grade ≥2) was present in 
the ND group (p=0.01) at all time points (Figure 1). 
 
 
 
Conclusion: Both treatment regimens have a comparable 
local, regional and distant control. However, fibrosis and 
more specifically fibrosis grade ≥2 is more prominent 
following upfront ND and CRT when compared to CRT alone.  
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Purpose or Objective: Chemo-radiotherapy (CRT) plays a 
major role in the management of patients with locally 
advanced squamous cell carcinoma of head and neck (LA-
SCCHN). However, loco-regional (LR) failure remains a 
significant problem due to the resistance to radiotherapy and 
chemotherapy. Inhibitors of Apoptosis Proteins (IAPs) are 
expressed in various cancers and are able to block caspase 
activation and modulate NF-kB signalling pathways. As such, 
they represent attractive targets to overcome resistance to 
both chemo- and radio-therapy. Debio 1143 is a potent 
orally-available IAP antagonist currently in clinical 
development able to radiosensitize and ameliorate the 
effects of platinum derivatives in multiple SCCHN models 
both in vitro and in vivo. A previous phase I study showed 
Debio 1143 as a single agent was well tolerated up to 400 
mg/day q14d21. This Phase I study defined the dose limiting 
toxicities (DLTs), maximum tolerated dose (MTD), safety, 
pharmacokinetic (PK) and pharmacodynamic (PD) of Debio 
1143 in combination with CRT. 
 
Material and Methods: Treatment-naïve LA-SSCHN (stage 
III/IV), negative HPV status for oropharynx, were treated 
with CRT (70 Gy in 7 weeks + cisplatin 100 mg/m2 every 3 
weeks) and escalating doses of Debio 1143, administered 
orally once daily on days 1-14 every 3 weeks for a maximum 
of 3 cycles. The starting dose of Debio 1143 was 100 mg/day. 
Doses were escalated using a Bayesian Continuous 
Reassessment Method (CRM) until MTD, based on dose 
limiting toxicities (DLTs) observed within the first 9 weeks 
